LICENSE AGREEMENTLicense Agreement • December 6th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • California
This License Agreement (the “Agreement”) is effective as of April 4, 2018 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and IMMUNOMEDICS, INC., a Delaware corporation (“Licensee”), each located at the respective address set forth in Section 13.15 below, with respect to the facts set forth below.
Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of...Confidential Treatment • December 6th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Letter of Intent (this “LOI”) is entered into between Immunomedics, Inc., a corporation with its principal office located at 300 The American Road Morris Plains, NJ 07950, USA (“Immunomedics”), and BSP Pharmaceuticals S.p.A., having a place of business at via Appia km 65,561 04013 Latina Scalo (LT), Italy (“BSP”), effective as of February 26, 2018 (the “Effective Date”).
